Details

Autor(en) / Beteiligte

• Ishida, Y.I.
• Kayama, T.
• Kibune, Y.
• Nishimoto, S.
• Koike, S.
• Suzuki, T.
• Horiuchi, Y.
• Miyashita, M.
• Itokawa, M.
• Arai, M.
• Ogasawara, Y.

Titel

Identification of an argpyrimidine-modified protein in human red blood cells from schizophrenic patients: A possible biomarker for diseases involving carbonyl stress

Ist Teil von

• Biochemical and biophysical research communications, 2017-11, Vol.493 (1), p.573-577

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2017

Quelle

ScienceDirect

Beschreibungen/Notizen

• Argpyrimidine (ARP) is an advanced glycation end product thought to be generated from a reaction between methylglyoxal and arginine residues in proteins. In this study, we observed marked accumulation of an approximately 56 kD protein, reactive to anti-ARP antibodies, in the red blood cells (RBCs) of some patients with refractory schizophrenia. This ARP-modified protein was purified from the blood of schizophrenic patients and identified as selenium binding protein 1 (SBP1) by LC-MS/MS. This is the first report of ARP-modified proteins accumulating in RBCs of patients with diseases involving carbonyl stress. We also observed high accumulation of ARP-modified SBP1 in the RBCs of patients with chronic kidney disease. Therefore, this modified protein may be a novel marker of carbonyl stress. [Display omitted] •An argpyrimidine-modified protein was accumulated in erythrocyte from schizophrenic patients.•We identified the argpyrimidine-modified protein in erythrocyte as selenium binding protein 1.•The argpyrimidine-modified SBP1 is a possible marker of carbonyl stress-related diseases.•Metabolic error of methylglyoxal may be involved in onset of carbonyl stress-type schizophrenia.